Complex functions of mutant p53 alleles from human prostate cancer

Prostate

Volumn 51, Issue 1, 2002, Pages 59-72

  Shi, Xu Bao ^a   Nesslinger, Nancy J ^a   Deitch, Arline D ^a   Gumerlock, Paul H ^a   Devere White, Ralph W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dominant negative; Gain of function; Loss of function; P53; Prostate cancer

Indexed keywords

CYCLINE; INTERLEUKIN 6; MULTIDRUG RESISTANCE PROTEIN; MUTANT PROTEIN; PROTEIN P53;

ALLELE; ARTICLE; CELL ASSAY; CELL CYCLE; CELL CYCLE S PHASE; CONTROLLED STUDY; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION;

ALLELES; BLOTTING, WESTERN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FLOW CYTOMETRY; GENES, P53; HUMANS; MALE; MUTAGENESIS, SITE-DIRECTED; PROSTATIC NEOPLASMS; S PHASE; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036535482     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10072     Document Type: Article

References (60)

1. Surfing the p53 network
2. The p53 network
3. Tumor suppressor p53: Regulation and function
4. The p53 tumour suppressor gene
5. p53 is required for radiation-induced apoptosis in mouse thymocytes
6. Molecular epidemiology of human cancer: Contribution of mutation spectra studies of tumor suppressor genes
7. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations
8. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53
9. Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBP beta (NF-IL6) activity by p53 species
10. Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy
11. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain
12. Gain of function mutations in p53
13. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients
14. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome
15. The role of the p53 tumor suppressor gene in prostate cancer: A possible biomarker?
16. p53: At the crossroads of molecular carcinogenesis and molecular epidemiology
17. p53 in prostate cancer: Frequent expressed transition mutations
18. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer
19. Molecular heterogeneity in prostate cancer: Can TP53 mutation unravel tumorigenesis?
20. Laser capture microdissection: Molecular analysis of tissue
21. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors
22. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma
23. Alteration of the tumorsuppressor gene p53 in a high fraction of hormone refractoryc prostate cancer
24. Association of p53 mutations with metastatic prostate cancer
25. Use of a yeast assay to detect functional alterations in p53 in prostate cancer: Review and future directions
26. Cancer statistics
27. Pathology of the prostate
28. A simple p53 functional assay for screening cell lines, blood, and tumors
29. Dominant-negative p53 mutations selected in yeast hit cancer hot spots
30. p53 oncogene mutations in human prostate cancer specimens
31. TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin
32. Screening the p53 status of human cell lines using a yeast functional assay
33. Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo
34. Constitutive expression of the cyclin-dependent kinase inhibitor p21 is transcriptionally regulated by the tumor suppressor protein p53
35. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells
36. Inhibition of viral and cellular promoters by human wild-type p53
37. Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line
38. Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter
39. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay
40. Temperature-sensitive mutant p53 (ala143) interferes transiently with DNA-synthesis and cell-cycle progression in Saos-2 cells
41. Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control
42. In vitro analysis of the dominant negative effect of p53 mutants
43. p53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer
44. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent
45. Mechanisms of p53-mediated apoptosis
46. Predicting biological aggressiveness in prostate cancerdesperately seeking a marker
47. Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer
48. Proliferative index determination in prostatic carcinoma tissue: Is there any additional prognostic value greater than that of Gleason score, ploidy and pathological stage?
49. S-phase fraction of human prostate adenocarcinoma studied with in vivo bromodeoxyuridine labeling
50. Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: Implications for prognosis and response to endocrine therapy
51. DNA ploidy, S phase fraction and G2 fraction as prognostic determinants in prostatic adenocarcinoma
52. Pathological and clinical associations of Ki-67 defined growth fractions in human prostatic carcinoma
53. Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma
54. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy
55. Accelerated tumor proliferation rates in locally recurrent prostate cancer after radical prostatectomy
56. Prostate cancer: Indicators of aggressiveness
57. Implication of cell kinetic changes during the progression of human prostatic cancer
58. Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle
59. Racial differences in clinically localized prostate cancers of black and white men
60. Gain-of-function mutations in the tumor suppressor gene p53